Clinical Trials
6 trialsNCT03878199 2026-04-24
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01251965 2025-06-08
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02152956 2024-01-30
VOYAGE
MacroGenics
Phase 1/2 Terminated
NCT01712659 2023-01-10
Ruxolitinib for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02587598 2021-12-08
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated